FOUNDATION FIGHTING BLINDNESS
Driving Research SAVING SIGHT
ANNUAL REPORT 2016
Table of Contents

Chairman's Message ............................................. 1
CEO Report ....................................................... 2
2016 Research Progress Highlights ......................... 3 – 4
Gordon and Llura Gund Family Challenge ............... 5
Treasurer's Report ............................................... 6 – 8
Board of Directors .............................................. 9
Scientific Advisory Board .................................... 10 – 12
National Trustees ............................................. 13 – 14
FFB Staff ............................................................ 15
National Chapters ............................................... 16

Gift Planning
Please consider remembering the Foundation Fighting Blindness as part of your will, trust or other estate plan. For more information visit our planned giving website at http://myplantofightblindness.org/
Chairman’s Message

David Brint, Chairman

Welcome to the 2016 annual report of the Foundation Fighting Blindness. As this is the beginning of my tenure as the Foundation’s chair, having replaced a legend, Gordon Gund, I am particularly honored to bring you this report. Again this year, we have exciting news to share.

During its 46-year history, the Foundation, through its investments, has supported the most promising research on potential treatments for inherited retinal degenerations being done across the globe. These investments have enabled a new level of understanding of how the retina works and what goes wrong when retinal cells stop working. They have also led to breakthrough discoveries in the search for cures. The strongest evidence of these results is the number of potential therapies moving out of the lab into clinical trials and toward the marketplace. For example, Spark Therapeutics is seeking U.S. Food and Drug Administration (FDA) approval for its gene-replacement therapy for a form of Leber congenital amaurosis (LCA2). This therapy, intended to treat blindness caused by mutations in the RPE65 gene, has received both breakthrough therapy and orphan disease product designation by the FDA. If approved, it could become the first-ever approved gene therapy for an inherited retinal disease and the first for any inherited disease in the United States!

The Foundation has continued to pursue strategic goals in 2016 including attracting biotech and pharma companies into the field and funding research that can be pursued by these entities once proof of concept is provided. Also important is our focus on filling the gaps that will encourage pharma and biotech to pursue retinal disease clinical trials, including locating patient populations through the My Retina Tracker program, providing agreed-upon clinical endpoints measures and getting their use approved by the FDA, and conducting natural history studies so industry and the FDA can measure treatment progress. Our ProgStar program for Stargardt is concluding, and a new initiative in Usher syndrome is beginning. FFB has always been strategic about the way we deploy funds. Our goal is to maximize the leverage those funds bring to the field.

I invite you to spend a few minutes reading this report for much more information about the important advances being made in retinal disease research—many of them thanks to Foundation Fighting Blindness funding. There is tremendous reason to be optimistic about the potential for vision-restoring treatments. But, as we marvel at the advances the vision science community has made, we also need to remember there is much more work to be done. And, in most cases, the most expensive part of the work—clinical trials and actually moving treatments to the patients who need them—is still ahead of us.

In short, we have much to be proud of. And lots more work to do, science to invest in, and money to raise. My pledge to you is that my colleagues in FFB’s leadership and I will continue to steward your donation dollars carefully and strategically based on the guidance of our world-class Research Oversight Committee and our Scientific Advisory Board.

I have a vision of the future I’m sure you share. It’s a future in which a family receiving the bad news that a loved one is losing or at risk of losing their vision due to a retinal degenerative disease is also told about their treatment options! Together we can make this vision a reality.

It is my privilege to serve as the chairman of the Foundation Fighting Blindness, but I cannot emphasize enough the critical role you, our generous donors and supporters, play in making the progress FFB has enabled possible.

Thank you for your continued support.

Sincerely,

David Brint
Bill Schmidt, CEO

Throughout its 46-year history, the Foundation Fighting Blindness has been the world leader in the field of retinal degenerative disease research. This year, the Foundation surpassed the $700 million milestone in money raised to advance this vision-saving research. That fundraising success, coupled with our work with pharmaceutical partners and the best retinal researchers in the world, provides over 10 million Americans and millions more people worldwide who have lost vision due to retinal disease with the true promise of restored sight.

The Foundation is led by a remarkable group of volunteers and is advised by the best minds in retinal disease research in the world – please see pages 9-12 for our Board leadership and members of our Scientific Advisory Board. In addition, we are also a local organization with 43 volunteer-led chapters across the United States. These dedicated volunteers raise funds, increase public awareness, and provide support to families affected by retinal diseases in their communities.

Wise stewardship of donation dollars and strategic investments in research are ingrained values for the Foundation. We are extremely proud of how far our work has moved the field of retinal degenerative disease research. This year, thanks to accelerated progress in clinical and translational research in labs across the United States and throughout the world, more FFB funds are being invested in later stages of the research continuum; that is, in the testing of specific treatments and potential cures in human subjects.

Over our history FFB has, on average, invested above 70 percent of our annual revenue budgets in research and public health education programs. We will continue to work to maintain our high average annual spending in these key program areas. For more information about FFB’s financial management, see the Treasurer’s Report on page 6.

Thanks to these sustained investments, Foundation-funded researchers are achieving remarkable success with a wide range of promising therapies for saving and restoring sight. Below are just a few examples of the research providing hope to millions affected by inherited vision loss.

Gene Therapy Restores Vision
The Foundation is funding translational research and clinical trials of gene therapy that have restored vision in patients who were virtually blind from a childhood form of retinitis pigmentosa.

Thanks to the treatment, they can now enjoy some of life’s simple joys, like reading and playing baseball.

Developing Drugs to Preserve Vision
The Foundation is funding research on potential drug therapies that work by slowing or preventing the loss of retinal cells, thereby saving vision. Many of these treatments are cross-cutting, meaning they’re designed to work for a wide range of retinal conditions, regardless of the genetic defect.

Harnessing the Power of Stem Cells
Foundation-funded researchers are using stem cells derived from a variety of sources, including a person’s own skin, to create healthy retinal cells that can potentially restore vision. Stem-cell treatments hold great promise for people with advanced vision loss.

Funding the Best in Retinal Research
The Foundation has funded studies at hundreds of prominent institutions throughout the world, including, but not limited to:

- Wilmer Eye Institute, Johns Hopkins University School of Medicine
- Massachusetts Eye and Ear Infirmary, Harvard Medical School
- Institut de la Vision, Paris, France
- Moorfields Eye Hospital, University College London
- Scheie Eye Institute, University of Pennsylvania

These impressive advancements would not be possible without the generous support of our donors. We can all feel very good about the progress being made, but let us remember there is also a lot more work to do. I hope we can count on your continued support.

If you have questions, I invite you to contact me at BSchmidt@FightBlindness.org.

Sincerely,

Bill
While finding treatments and cures for inherited retinal diseases is a decades-long pursuit, the year-over-year progress, including that made this year, is extremely encouraging. Specifically, the Foundation’s investments in research and technology and its pursuit of biotech and pharmaceutical partners are achieving remarkable success in the discovery and testing of a wide range of promising therapies to prevent, treat, and cure blindness caused by retinal degeneration.

"Due to the Foundation Fighting Blindness’ unwavering support of research over its 46-year history, retinal degenerative disease research is leading the medical field in advancing treatments for inherited diseases into the clinic. As a result, the prospect for many treatments for inherited retinal degeneration has never been more promising. FFB support has allowed these groundbreaking advances to be achieved," said Stephen Rose, PhD, FFB Chief Research Officer.

Nowhere is this accelerating progress more evident than in human studies – clinical trials – for promising vision-saving therapies. As the "era of clinical trials" continues, FFB’s unique role in building bridges between early lab and translational research and the considerable financial resources that later-stage human clinical trials require – resources that can only be provided by the pharmaceutical industry – is particularly evident.

The following are examples of the impressive research progress that has been made over the past year. The Foundation Fighting Blindness played a critical role in the advancement of all these emerging therapies.

Pursuing FDA Approval for a Gene Therapy

Thanks to vision restoration in a clinical trial for children and young adults who were virtually blind, Spark Therapeutics, a Philadelphia company which has its roots in FFB funding, has sought U.S. Food and Drug Administration (FDA) approval for its RPE65 gene-replacement therapy. The treatment helps restore vision by delivering copies of a light-sensitive gene to surviving cells in the retina. If approved by the FDA, it will be the first approved gene therapy for the eye and the first for any inherited condition in the United States!

Big Pharma Investment in Promising Retinal Disease Therapies

In 2015, RetroSense Therapeutics received FDA authorization to launch a clinical trial of its optogenetic gene therapy. By harnessing surviving cells in the retina, the emerging treatment holds promise for restoring some vision to people who are completely blind, regardless of the gene mutation causing their disease.

In 2016, the company began treating the trial’s first patients. No inflammation or ocular adverse events were seen in any of the trial participants, and biological activity within the eye was confirmed. Thanks to the potential of this therapeutic approach, the international pharmaceutical company Allergan purchased RetroSense for $60 million.

In 2016, SparkTherapeutics, the Philadelphia-based, gene-therapy company responsible for developing a treatment targeting retinal diseases caused by mutations in the RPE65 gene described above, purchased Genable Technologies, Ltd., an Irish bio-pharmaceutical company developing a gene therapy, Rhonova™, for the treatment of autosomal dominant retinitis pigmentosa (adRP).

In 2016, Biogen and AGTC established a milestone-based collaborative development and commercialization program for XLRS and XLRP gene therapies exceeding $1 billion in total funding. Biogen will be granted a license to the XLRS and XLRP
programs and the option to license discovery programs for three additional indications at the time of clinical candidate selection.

**Stem Cells for RP Move Into Human Studies**

In 2015, two companies, ReNeuron (U.K.) and JCyte (California), received FDA authorization to launch clinical trials of their stem-cell therapies for retinitis pigmentosa (RP).

In 2016, both companies reported they were treating patients without any serious adverse events. While ReNeuron did not disclose how many participants had received its cell injections, JCyte reported they had treated nearly two dozen people. Both clinical trials, which are initially focused on safety, are the first-ever stem-cell trials for RP.

**Gene Therapy Leads to Sustained Vision Benefits**

In 2016, researchers at the University of Oxford (U.K.) reported that the vision benefits of its gene therapy for people with choroideremia had been sustained for the first patients treated in its clinical trial, which launched in 2013. Gene therapy clinical trials for people with choroideremia are now underway (or being launched) at Bascom Palmer Eye Institute in Miami, the University of Alberta, Children’s Hospital of Philadelphia, the University of Pennsylvania, and Massachusetts Eye and Ear Infirmary.

In 2016, several other clinical trials for potential treatments are advancing impressively, including gene therapy studies for achromatopsia, Usher syndrome, Stargardt disease, and retinoschisis.

**FFB’s Clinical Research Institute Advances Human Research**

In 2016, the Foundation’s Clinical Research Institute continued to boost the global retinal research field with patient natural history studies such as ProgSTAR (Stargardt disease); its patient registry, MyRetinaTracker.org; and a consortium of clinical experts ready to quickly and effectively launch more clinical trials for vision-saving therapies. In 2017, the consortium will launch a natural history study for people with Usher syndrome and RP caused by mutations in the gene USH2A.

**SparingVision**

The Foundation Fighting Blindness Clinical Research Institute (FFB-CRI), Bpifrance (BPI), and the Fondation Voir et Entendre (FVE) announced the formation of SparingVision, a company headquartered in France, to advance a promising, emerging therapy for the treatment of blinding retinal disease retinitis pigmentosa (RP) into a clinical trial and, ultimately, out to the international marketplace. A total of €15.5 million in tranche funding has been announced, with FFB-CRI and BPI each investing €7 million and FVE providing €1.5 million. SparingVision’s goal is to launch a clinical trial for RdCVF in 2019.

**FDA Clinical Trial Endpoints Meeting**

FFB-CRI — along with the FDA, National Eye Institute (NEI), and the Association for Research in Vision and Ophthalmology (ARVO) — hosted a one-day public workshop to review clinical trial design considerations and outcome measures for potential treatments for inherited retinal diseases. As a result of the meeting, the FDA validated an endpoint measurement tool known as EZ Area, which efficiently and effectively measures viable photoreceptors in a patient’s retina. EZ Area, developed by researchers funded by FFB-CRI, will greatly help drug developers and pharmaceutical companies design and launch human studies for treatments for people with retinitis pigmentosa.

**Therapy Review Meetings**

FFB-CRI organized and hosted a dozen therapy review meetings that brought together the world’s leading drug development experts to evaluate the status of emerging stem-cell, gene, and pharmaceutical treatments for inherited retinal diseases. The goal of these meetings was to determine what preclinical studies companies and researchers needed to do to move potential therapies into human studies. The meetings also helped FFB-CRI determine which companies and treatments warranted investment.
Gordon and Llura Gund Family Challenge Raised More Than $111 Million for Retinal Disease Research

A Message of Thanks!

In April 2014, we launched the Gordon and Llura Gund Family Challenge. Our goal was to raise in total gifts and multiyear pledges more than $100 million for research before June 30, 2016, by matching any new or increased commitments to the Foundation of $25,000 or more. Our purpose for doing this was to accelerate the progress of the Foundation’s already highly promising research efforts to find treatments and cures for retinal degenerative diseases.

We are thrilled to be able to share with you that the Challenge was a huge success. Due to the generosity of its 260 donors, and gift matching funds from us, the challenge raised $111.6 million. These funds, under the stewardship of FFB’s Research Oversight Committee, will now be invested into research that moves promising therapies from the lab into clinical trials and, eventually, to the patients who need them. Importantly, this infusion of funds will allow FFB to increase the size and scope of its research portfolio, including the number of studies that can be funded in emerging therapies that show promise across multiple diseases, among them, gene and stem-cell treatments.

When we joined the Berman family and others 46 years ago to begin the journey to end blindness, very little was known about the retina, retinal degenerative diseases, and the visual process. At that time, almost no research was going on to build this knowledge, and no clinical trials were in the offing for possible treatments.

Today, thanks in large part to FFB’s persistently innovative research support backed by thousands of donors and volunteers over the years, 20 such trials are underway with many more in the pipeline. The addition of the match program’s support, coupled with the ongoing generosity of all FFB’s donors and volunteers, will ensure that amazing research advancements in our understanding of inherited retinal disease and treating it will continue and accelerate.

Our great thanks to the Gund Challenge donors and all FFB supporters who are literally helping to preserve and restore sight!

With our warmest best wishes,

Gordon Gund  
Co-Founder, Chairman Emeritus

Llura Gund  
Co-Founder, President, New Jersey Chapter

“Gordon and Lulie and the match they enabled are an incredible and everlasting gift to all of us and the thousands that will benefit. This match will expand and perpetuate the FFB mission. It will create more momentum, more clinical trials, more progress, more success. Sight.”

BRUCE AND BONNIE SAWYER  
Bruce and Bonnie Sawyer were donors to the Gordon and Llura Gund Family Challenge.
Treasurer’s Report

Haynes Lea, Treasurer

I have the pleasure of providing you the statement of Foundation Fighting Blindness’ activities and financial position for the fiscal year that ended on June 30, 2016. Thanks to the continued generosity of our donors, the Foundation is in a strong financial position to continue its work to advance research on treatments and cures for retinal degenerative diseases.

Fiscal year 2016 was a particularly momentous one for the Foundation due to the unprecedented success of the Gordon and Lura Gund Family Challenge. As you have read elsewhere in this report, the challenge surpassed its goal, raising $111.6 million to further FFB’s investment in vision-saving research and treatments. The success of the Gund Challenge will allow us to increase the size and scope of our research investments in preclinical and clinical trial work, leading to what we expect to be broad research and treatment applications.

We will now embark on careful stewardship of the Challenge funds guided by FFB’s Research Oversight Committee’s strategic plan. The plan calls for a $20 million investment in basic discovery, translational, and proof-of-concept research every year for the next five years. The committee, after evaluating the potential of current retinal disease research and related science, including gene and stem-cell therapy, concluded that this level of support for preclinical investigative work has the best chance of leading to U.S. Food and Drug Administration (FDA) authorized clinical trials and ultimately FDA-approved treatments.

Finally, our direct response membership program added $2 million in annual revenue.

In summary, our strong financial position is allowing FFB to make significant investments in critical, emerging research including in such promising areas as stem-cell and gene therapies. I join all those affected by retinal degenerative diseases in thanking our many donors for their generous support of our mission. Our promise in return is to remain good stewards of these dollars and maintain our high annual investments in the key program areas of research and public health education.

Sincerely,

[Signature]

In other fundraising, FFB’s dinners and other social events continue to do well. FY 2016 revenue from the events program was $9.9 million. FFB’s VisionWalk program is now in its 11th year and has surpassed the $40 million mark for earned revenue.
Actual Results—Year Ending June 30, 2016

Statement of Activities

REVENUE AND SUPPORT
Contributions ........................................... $55,074,000
Special events, net of direct ................. $8,168,000
Bequests .............................................. $4,134,000
Other revenue ....................................... $4,899,000
Total Revenue ....................................... $72,275,000

EXPENSES
Research ................................................ $16,352,000
Public Health Information ..................... $2,260,000
Management ......................................... $2,729,000
Fundraising .......................................... $7,228,000
Total Expenses .................................... $28,569,000
Change in unrestricted net assets ............ $6,849,000
Change in temporarily restricted net assets $34,167,000
Change in permanently restricted net assets $2,690,000
Total Change in Net Assets .................... $43,706,000

Statement of Financial Position

ASSETS
Cash and investments ......................... $96,910,000
Pledges receivable, net ....................... $52,028,000
Other assets ......................................... $1,474,000
Trusts and other funds ....................... $7,600,000
Fixed assets, net ................................ $1,630,000
Total Assets ....................................... $159,642,000

LIABILITIES
Accounts payable and accrued liabilities .... $3,211,000
Research grants payable ...................... $9,081,000
Deferred revenues ............................... $1,146,000
Liabilities under trusts and other funds .... $1,614,000
Total Liabilities ................................. $15,052,000

NET ASSETS
Unrestricted net assets ....................... $8,730,000
Unrestricted net assets for research ......... $14,238,000
Temporarily restricted net assets .......... $118,432,000
Permanently restricted net assets .......... $3,190,000
Total net assets ............................... $144,590,000
Total Liabilities and Net Assets .......... $159,642,000

Year Ahead—Target Spending Allocations

70% Research Including Grants

17% Fundraising

7% Public Health Education

6% Administration
2016 Research Investments

In its focused pursuit of preventions, treatments, and cures for the entire spectrum of retinal degenerative diseases, the Foundation evaluates and selects for support a diverse research portfolio. That portfolio is focused on six priority areas: genetics, gene therapy, the cellular mechanisms of retinal diseases, clinical structure and functional relationships, novel medical therapy, and regenerative medicine.

**Highlights of 2016 Funding**

Research Center grant funding .................. $5,490,714
Individual Investigator grant funding ........... $5,042,225
Alan Laties Career Development grant funding ....... $742,775
Clinical Research Institute clinical studies and grant funding .............................................. $2,085,852

Total 2016 funding: ...................................... $13,361,566

For a complete list of all 2016 Foundation Fighting Blindness grant recipients, please visit: [www.blindness.org/funded-grants](http://www.blindness.org/funded-grants).

**Grant Spending**

- **29%** Clinical Structure and Functional Relationships
- **21%** Genetics
- **18%** Gene Therapy
- **14%** Novel Medical Therapy
- **14%** Cellular and Molecular Mechanisms
- **4%** Regenerative Medicine
Board of Directors

OFFICERS

David Brint
Chairman
Co-founder and Principal, Brinsore Development
Northbrook, Illinois

Edward Russnow
Vice Chairman, Development
President
MAC Products, Inc.
Kearny, New Jersey

Warren Thaler
Vice Chairman,
Board Development & Communications
President
Gund Investment Corporation
Ardmore, Pennsylvania

Gordon Gund
Co-founder, Director - Chairman Emeritus
Chairman and CEO
Gund Investment Corporation
Princeton, New Jersey

Haynes Lea
Treasurer
Partner
Robinson, Bradshaw & Hinson, PA
Charlotte, North Carolina

Jonathan Steinberg, MD
Vice Chairman, Research
Professor of Medicine
University of Rochester School of Medicine and Dentistry
Rochester, New York

Yvonne Chester
Secretary
Napa, California

DIRECTORS

Steve Alper
Director
Managing Director
Stifel Financial
New York, New York

Marilyn Green
Director
Owner
Marilyn’s Agency
Greensboro, North Carolina

Evan Mittman
Director
Armonk, New York

Edward Babin
Director
President
Metro Fire Protection
Boo mum, Pennsylvania

Robert Heidenberg
Director
President and CEO
Heidenberg Properties Group
Closter, NJ

Karen Petrou
Director
Co-founder and Managing Partner
Federal Financial Analytics, Inc.
Washington, DC

William Carty
Director
Herndon, Virginia

Sherri Kroonenberg
Director
Littleton, Colorado

Bruce Sawyer
Director
Baltimore, Maryland

Jason Ferreira
Director
Owner
Ferreira Foodtown
Greater New York City Area

Janni Lehrer-Stein
Director
San Francisco, California

Maryrose Sylvester
Director
President and CEO
Current, powered by GE
Boston, Massachusetts

Bradford Manning
Director
Managing Director
Tiger Lily Capital
New York, New York
Scientific Advisory Board

CHAIR

Jacque Duncan, MD
Professor of Clinical Ophthalmology
Beckman Vision Center
University of California, San Francisco

VICE CHAIRS

Stephen P. Daiger, PhD
T5 Matney Professor of Environmental & Genetic Sciences
Human Genetics Center
University of Texas Health Science Center

Frederick Ferris, III, MD
Clinical Director
National Eye Institute

John Flannery, PhD
Associate Director, Helen Wills Neuroscience Institute
University of California at Berkeley

José A. Sahel, MD
Professor of Ophthalmology
Institut de la Vision
Paris, France

Richard G. Weleber, MD
Professor and Chairman
Department of Ophthalmology
University of Pittsburgh School of Medicine

Alan M. Laties, MD
Professor of Ophthalmology in Neurology
Department of Ophthalmology
University of Pennsylvania Medical School

Marco Zarin, MD, PhD
Professor and Chair
Institute of Ophthalmology and Visual Science
Rutgers New Jersey Medical School

Eric A. Pierce, MD, PhD
Director, Berman-Gund Laboratory
Massachusetts Eye & Ear Infirmary
Harvard Medical School

MEMBERS

Gustavo Aguirre, VMD, PhD
Professor of Medical Genetics and Ophthalmology
School of Veterinary Medicine
University of Pennsylvania

Isabelle Audo, MD, PhD
Assistant Professor, Centre Hospitalier National des Quinze and
Department of Genetics
Institut de la Vision
Paris, France

Bela Anand Apte, MBB, PhD
Professor, Cell Biology
Cole Eye Institute
Cleveland Clinic Foundation

Radha Ayyagari, PhD
Associate Professor, Ophthalmology
Shiley Eye Center
University of California, San Diego

John D. Ash, PhD
Associate Professor, Ophthalmology
University of Florida College of Medicine

William A. Beltran, DVM, PhD
Associate Professor, Ophthalmology
School of Veterinary Medicine
University of Pennsylvania
Scientific Advisory Board

Paul S. Bernstein, MD, PhD
Professor, Ophthalmology & Visual Sciences
Moose Eye Center, University of Utah

David G. Birch, PhD
Director, Rose Silverthorne Retinal Degenerations Laboratory
Retina Foundation of the Southwest

Catherine Bowes Rickman, PhD
Associate Professor, Department of Ophthalmology
Duke University Medical Center

Franz P.M. Cremers, PhD
Professor, Department of Human Genetics
Radboud University Nijmegen Medical Centre

Eugene de Juan, Jr., MD
Professor, Ophthalmology
Beckman Vision Center
University of California, San Francisco

Lucian V. Del Priore, MD, PhD
Chair, Ophthalmology and Visual Science
Yale University School of Medicine

Debra Farber, PhD
Professor, Ophthalmology
Jules Stein Eye Institute
University of California, Los Angeles

G. Jane Farrar, PhD
Co-Director, Ocular Genetics Unit School of Genetics and Microbiology
Trinity College Dublin

Gerald A. Fishman, MD
Director, the Pangere Center for Hereditary Retinal Diseases
The Chicago Lighthouse for People Who are Blind or Visually Impaired

Steven J. Fliesler, PhD
Professor, Vice-Chair and Director of Research
Department of Ophthalmology
University at Buffalo State University of New York (SUNY-UB)

David M. Gamm, MD, PhD
Associate Professor, Ophthalmology & Visual Sciences
Weisman Center
University of Wisconsin-Madison

Morton F. Goldberg, MD
Professor, Ophthalmology
Willmer Eye Institute
Johns Hopkins Hospital

William W. Hauswirth, PhD
Professor, Ophthalmology and Molecular Genetics
University of Florida College of Medicine

Elise Héon, MD, FRCSc
Ophthalmologist-in-Chief, Ophthalmology and Vision Sciences
The Hospital for Sick Children
University of Toronto

Joe G. Hollyfield, PhD
Director, Department of Ophthalmic Research
Cole Eye Institute
Cleveland Clinic Foundation

Leslie G. Hyman, PhD
Professor, Department of Preventive Medicine
Stony Brook University Medical Center

Alessandro Iannaccone, MD, MS
Director, Center for Retinal Degenerations and Ophthalmic Genetic Diseases
Duke University Medical Center
Duke Eye Center

Samuel G. Jacobson, MD, PhD
Director, Center for Hereditary Retinal Degenerations and Retinal Function
Department of Ophthalmology
University of Pennsylvania

Tiansen Li, PhD
Chief, Retinal Cell Biology & Degeneration Section
Neurobiology and Regeneration Laboratory
National Eye Institute
National Institutes of Health

Roderick R. McInnes, MD, PhD
Director, Lady Davis Institute
Jewish General Hospital

Muna I. Naash, PhD
Professor, Biomedical Engineering
Department of Biomedical Engineering
University of Houston

Jeremy Nathans, MD, PhD
Professor, Molecular Biology and Genetics
Johns Hopkins University School of Medicine

Gary D. Novack, PhD
President
Pharologic Development, Inc.

Mark Pennesi, MD, PhD
Associate Professor
Chief, Ophthalmic Genetics Division
Oregon Health & Science University
Scientific Advisory Board

Thomas Reh, PhD
Director, Neurobiology and Behavior
Department of Biological Structure
University of Washington

Bärbel M. Rohrer, PhD
Professor, Ophthalmology and Neurosciences
Medical University of South Carolina

Johanna M. Seddon, MD, ScM
Director, Ophthalmic Epidemiology and Genetics Service
New England Eye Center
Tufts University School of Medicine

Hendrik P.N. Scholl, MD, MA
Professor and Chairman, Department of Ophthalmology
University of Basel

Janet R. Sparrow, PhD
Professor, Ophthalmic Science
Department of Pathology and Cell Biology
Columbia University

Douglas Vollrath, MD, PhD
Associate Professor, Genetics
Stanford University School of Medicine

David S. Williams, PhD
Director, Jules Stein Eye Institute
UCLA School of Medicine

Russell N. Van Gelder, MD, PhD
Professor and Chair, Ophthalmology
Department of Ophthalmology
University of Washington

Michael J. Young, PhD
Director, Minde de Gunzburg Research Center for Ocular Regeneration
Sheppards Eye Research Institute
Department of Ophthalmology
Harvard Medical School

Donald J. Zank, MD, PhD
Professor of Genetic Engineering & Molecular Ophthalmology
Wills Eye Institute
Johns Hopkins University School of Medicine

EMERITUS MEMBERS

Robert E. Anderson, MD, PhD
Department of Ophthalmology
University of Oklahoma Health Sciences Center

Jean Bennett, MD, PhD
Professor, M.K. Kirby Center for Molecular Ophthalmology
Schepis Eye Institute
University of Pennsylvania School of Medicine

Eliot L. Berson, MD
Director, Berman-Card Laboratory
Massachusetts Eye & Ear Infirmary
Harvard Medical School

Dean Bok, PhD
Director, Retinal Cell Biology Laboratory
Jules Stein Eye Institute
University of California, Los Angeles

John E. Dowling, PhD
Professor of Ophthalmology
The Biological Laboratories
Harvard University

William J. Kimberling, PhD
Director, Center for the Study and Treatment of Usher Syndrome
Flanagan’s Boys’ Home
Boys Town National Research Hospital

Mathew M. LaVail, PhD
Professor of Anatomy and Ophthalmology
Beckman Vision Center
University of California, San Francisco

Vincent H. L. Lee, PhD
Professor and Director
School of Pharmacy
Chinese University of Hong Kong

Edwin Stone, MD, PhD
Seaburn-Hauser Chair in Molecular Ophthalmology
Department of Ophthalmology and Visual Sciences
University of Iowa Hospitals & Clinics

Andreas Wenzel, PhD
Medical Affairs Manager
Novartis Pharma

Gregory S. Hageman, PhD
President, Professor of Ophthalmology & Visual Sciences
John A. Moran Eye Center
University of Utah
National Trustees

David Alexander
Peter Alexander
Terry Pink Alexander
Pamela Allen
Julie Anderson
Greg Austin
Hal Barron, MD
Daniel Bergstein
Jordan Bergstein
Beverly Berman
Thomas Bernardin
Joseph Bier
Jay Blackman
LuAnn Blackman
Aryeh Bourkoff
Betsy Bradley
Denise Brown
Steven Browne
Scott Burt
Melissa Campbell, MD
Patricia Campbell-Stichweh
Mindy Caplan
Shoshana Cardin
William Chatlos
Pamela Chestnut
Robert Cleveland
Alice Cohen, MD
Christopher Coleman
Joan Crowley
Peter Crowley
Thomas Curley
Glen Davidson
Daniel Day
Eugene de Juan, Jr., MD
David Detrisac, MD
Steven Dezii
Betty Dominick
James Dominick
Ralph Donnelly
Christina Fasser
Jennifer Ferreira
David Finkelstein
Harriet Finkelstein
Robert Finzi
William Fischer
Edward Gollob
Jane Gomez
Ramon Gomez
Dean Green
Bruce Grieve
Grant Gund
Lara Gund
Llura Gund
G. Zachary Gund
Lawrence Halperin, MD
Steve Hamby
Howard Hirsch
Board of Directors Emeritus
Roger Horchow
Laura Hughes
Robert Hughes
William James Jr.
Tracy Johns, EdD
Joseph Kahl
Judy Kahl
Alan Kahn
Anne Katcher
Gary Katcher
Mitch Katcher
Jody Kelly
Gil Kliman, MD
Ann Korologos
Louis Kreisberg
J. Gilmour Lake
Alan Landis
Elizabeth Lea
Abigail LeBlanc
Linda Lechner
Nathan Light
National Trustees

William Link, PhD
David Luehrs
April Lufriu
Karen Luna
Stephen Mack
Kamal Majeed, PhD
Bryan Manning
Ronald Massman
James Mattix
Reston Mattix
Beatrice Mayer
William McCaughey
James McNiel
Wren McNiel
Nancy Mendelow
Debi Mittman
Karen Montagnese
Nicholas Montagnese
Jason Morris
Jill Morris
Leslie Morris
Robert Morris
Sean Moynihan
John Mozeliak
Jacob Myers
Jack Nudel, MD

Harry Oakes
Pat O’Callaghan Sr.
Igor Olenicoff
Dale Pollak
Nancy Pollak
Louis Posen
Noah Rabinsky
Walter Raineri
Mitch Reiter
Kenneth Rietz
Holly Rush
John Saclarides
Mel Sahyun, PhD
Ginny Schott
James Schott, PhD
Ira Schulman
M. Rose Shane
Deborah Shaw
Jeremiah Shaw
Moira Shea
Stuart Slotnick
Iris Spiegel
Reuven Spiegel
Alan Spiro
Martha Steele

Barbara Stone
Jill Stone
Joel Stone
Michael Stone
Teri Ardeleigh Swift
Donna Burke-Tehaan
Frank Trainor
Meredith Tyree
Mark Valenziano
Michelle Veloce
George Villere
Lamar Villere
David Walsh
Peter Whinfrey
John Wilson, Jr.
William Woodall
Stephen Wynn
Eric Zankman
SENIOR STAFF

William T. Schmidt  
Chief Executive Officer

Stephen Rose, PhD  
Chief Research Officer

Patricia Zilliox, PhD  
Chief Drug Development Officer

Valerie Navy-Daniels  
Chief Development Officer

Lorraine Hirsch, CPA  
Chief Financial Officer

Patricia Dudley  
Chief Human Resources Officer

Annette Hinkle, CPA  
Chief Strategy Officer

HEADQUARTERS

7168 Columbia Gateway Drive, Suite 100  
Columbia, Maryland 21046  
410-423-0600

REGIONAL OFFICES

Chicago  
977 Lakeview Parkway, Suite 140  
Vernon Hills, IL 60061  
847-680-0100

Los Angeles  
10350 Santa Monica Blvd., Suite 250  
Los Angeles, CA 90025  
310-450-2910

New York  
80 Broad Street, Suite 3301  
New York, NY 10004  
212-244-1470

Raleigh  
4600 Marriott Drive, Suite 340  
Raleigh, NC 27612  
919-781-8014
National Chapters

NORTHEAST REGION

Boston
Martha Steele, President

Long Island
Karen Montagnese, President

New York City
Carl Gruber, President

Philadelphia
Heather Napolitano, President

Princeton
Uma Gund, President

Westchester/Fairfield
Anne Katcher, President

SOUTHERN REGION

Atlanta

Baltimore
Mindy Caplan, President

Charlotte
Trent Scovell, President

Greensboro (Triad)
Tom Serrin, President

Jacksonville
Adriann Keve, President

Montgomery County
Eric Fulton, President

Nashville (Middle TN)
Peggy Mitchell, President

Northern VA
Davida Luehrs, President

Orlando
Dan Day, President

Raleigh-Durham
Kristy Lee, President

South Carolina
Jennifer Kate Altman, President

Tampa Bay
April Lufitri, President

Virginia Beach (Hampton Roads)
Debra Laughlin, President

MIDWEST REGION

Chicago
Tom Weber, President

Cincinnati/N. Kentucky
Tim Smith, President

Cleveland
Greg Dubeczy, President

Columbus
Seth Porter, President

Eastern Michigan
Kathy Marcarth, President

Ft. Wayne
Rick Dahlstrom, President

Indiana
Gil Jamies, President

Kansas City
Terry Super, President

Memphis

Milwaukee
Bonita Jordan, President

Minneapolis
Julie Anderson, President

Pittsburgh

St. Louis
Jason Morris, President

WESTERN REGION

Arizona
Jacque Olsen, President

Bay Area
Henry K. Wong, President

Dallas
Neva Fairchild, President

Denver
Carmen Swick, President

Houston
Carley Colton, President

Las Vegas

Los Angeles

Orange County
Randy Wechter, President

San Antonio
Todd Dunn, President

San Diego
Jody Tadder, President

Seattle
Mike Hoag, President
**2016 Snapshot**

**Top-Left:** Singer-songwriter Judy Collins performed at a reception and dinner held at the Museum of Modern Art in New York to thank donors to the Gordon and Lluar Gund Family Challenge. The Challenge raised over $111,000,000 for new research. **Top-Right:** Udita Jain (left) and Alexa Ovalle (right) met at Visions 2016. Both have LCA. They enjoyed the conference and getting to know each other. **Bottom:** Dozens of 2016 Houston VisionWalk volunteers were guests on the morning program Great Day Houston to help promote the walk. A total of 360 walkers participated, including 34 teams, raising over $85,000.